Articles: function.
-
Critical care medicine · Mar 2014
Comparative StudySepsis Visits and Antibiotic Utilization in U.S. Emergency Departments.
To monitor the frequency of sepsis visits in U.S. emergency departments and assess the appropriateness of antibiotic utilization. ⋯ Explicitly diagnosed sepsis visits did not become more common during 1994-2009. Our data suggest that many emergency department patients with sepsis do not receive antibiotics until they arrive on the inpatient unit. When antibiotics are used among septic emergency department patients, drug-resistant bacteria are covered infrequently. These methods provide a simple approach to tracking the frequency with which sepsis is diagnosed among emergency department patients and to monitoring antibiotic therapy.
-
Pulmonary Function TestingSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: According to the predominant phenotype, patients suffering from Chronic Obstructive Pulmonary Oisease (COPO) may present varying and important nutritional profile alterations, up to extreme degrees of severe proteic-energetic malnutrition. In our study, Bioelectricallmpedance Analysis (BIA) has been used in the evaluation of nutritional status (with particular regards to body lean mass alterations) of patients suffering from COPDMETHODS: Up to now, 68 patients (46 M; mean age 70.6 yrs) affected by stable mild to very severe COPD (GOLD 2011 stages l-IV) were evaluated. All of them underwent body plethysmographic evaluation of pulmonary function, six-minute walking test (6MWT) and respiratory muscles strength evaluation (with maximum Inspiratory and expiratory pressures - MIP/MEP - assessment). Moreover, BIA variables were studied with Dietosystem Human Scan, that expresses either quantitative (BIA index) and qualitative (multifrequency relation and phase angle) body lean mass alterations. Furthermore, SIA data from a control age matched group were collected. ⋯ The following authors have nothing to disclose: Francesco De Blasio, Maria Grazia Santaniello, Francesca De Blasio, Giulia Miracco Berlingieri, Barbara Bellofiore, Luca ScalfiNo Product/Research Disclosure Information.
-
Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The cardiovascular complications(CVC) are the important causes of mortality/morbidity in OSAS. Hypoxia, vascular endothelial dysfunction and hypercoagulability are some of the pathophysiological mechanisms. In presence of hypoxia, hematocrit increases to maintain constant delivery of oxygen to the tissue. Hyperviscosity from increased hematocrit is one of the stimuli for atherosclerotic process. Mean platelet volume(MPV) is an indicator of platelet activation and was found to be an indicator for atherosclerosis. We investigated correlation between the hematocrit and MPV levels with the severity and response of OSAS to the CPAP therapy. ⋯ The following authors have nothing to disclose: Gülcan Çetin, Elif Kupeli, Serife Savas Bozbas, Füsun Öner EyüboğluNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
For stroke prevention in patients with atrial fibrillation and other indications new oral anticoagulants have been developed. These drugs are direct anticoagulants in contrast to the indirectly acting vitamin-K antagonists, which are used for decades as the only available drugs. ⋯ However, to transfer the benefit from the large scale studies to the real world conditions, physicians have to get clinical experience in using the new drugs. Especially drug interactions, impaired renal function and periinterventional bridging need special attention to ensure transfer of the new drugs benefits to daily life treatment.